I researched, and was forced to accept disability. This has led to yet conversational one in order to tell this ironic story in my memoir, Both Sides Now: A Journey from Researcher to Patient. taken almost 20 years and millions of research dol- lars, but our breakthrough in identifying alpha- synuclein has come full circle. On July 31, 2014, the Austrian drug development company AFFiRiS conducted a webinar in which it announced results totalwebcasting.com/view/?id=affiris). The trial, a four-month, Phase I safety and tolerability study, suggested some immunological and clinical effica- cy for Parkinson's participants, and it has opened pany, has also begun looking at targeting alpha-synuclein with a mon- oclonal antibody, PRX002. (I want to note that neither I nor any of my immediate family members have any financial connection or other con- flicts of interest regarding this vaccine or monoclonal antibodies.) could not be more relevant for me personally. My story has been cov- ered in several New Jersey newspapers, and Psychology Today has invited me to blog about my views from both sides of the white coat (http://www.psychologytoday.com/blog/neurogenetic-journey). If you decide to read my story, I hope you will enjoy the humor, celebrate the common bonds that sustained us at Robert Wood Johnson Medical 20 percent of the book's proceeds to the APDA. of alpha-synuclein pleted his fellowship in anterior segment and corneal surgery at Wills Eye Hospital. instructor at the Hospital of the University of Pennsylvania in July 2015." surgery to radiology and eventually interventional radiology. I began new training program at Staten Island University Hospital in July 2015." in Bridgewater. Hopkins University School of Medicine in July 2015. R e s i d e n t s Heart and Vascular Institute at Temple University School of Medicine. |